Johnson & Johnson (JNJ) Stock AnalysisJNJStock AnalysisJohnson & Johnson

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Johnson & Johnson is a good buy right now due to its strong financial performance, including a projected revenue of $100.6 billion for 2026, reflecting a 6.8% year-over-year increase, and a solid current price of $268.04, which is below the average analyst price target of $290. Additionally, the company has a robust gross margin of 68.33% and has consistently raised its dividend for 64 consecutive years, showcasing its commitment to returning value to shareholders. The main risk is the insider selling activity, which has increased by 159.20% over the last month, indicating potential concerns among insiders about the stock's future performance.

23 analysts cover JNJ: 12 rate it Buy, 8 Hold and 3 Sell. The average price target is 218.50.